Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Closed Formularies in Medicaid? Massachusetts Could Set Precedent

Executive Summary

State requests waiver from Centers for Medicare and Medicaid Services to use closed formulary in its Medicaid program as a way to lower prescription drug costs.

You may also be interested in...



US Medicaid Director Tsai Proposed Closed Formulary As Head Of Massachusetts Medicaid

Tsai will likely participate in a decision on whether to allow Tennessee to move ahead with changes to its Medicaid program that might include the flexibility to exclude drugs from coverage.

No Closed Formularies In Medicaid Without Forgoing Rebates, CMS Tells Massachusetts

US agency decision is a relief to manufacturers worried that the Massachusetts plan would lead to reduced drug access and heavier rebate burdens. 

Medicaid Reform: Trump Administration Pursuing Rebates Over 100%

States might also be able to test closed formularies in Medicaid as Trump Administration seeks stronger disincentives for price increases.

Related Content

Topics

UsernamePublicRestriction

Register

PS121712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel